WASHINGTON, CT, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Evexia Diagnostics, a leading provider of ...
The Illumina NovaSeq X adds to Agilus Diagnostics’ molecular testing portfolio through high-throughput sequencing and ...
Researchers found that an NHS test for ovarian cancer in premenopausal women performs poorly, with ultrasound‑based methods demonstrating increased accuracy.
Probius to develop AI-powered point-of-care screening technology, eliminating sample preparation requirements and ...
En Carta Diagnostics receives FDA Breakthrough Device Designation for EC Pocket Lyme test Breakthrough device status for rapid, Point-of-Need molecular diagnostic platform will fill critical gap in ...
Lucid's Q3 2025 showed 2,841 tests and $7.1 million in pro forma revenues billed, but only $1.2 million could be ...
Fungal testing in outpatient community-acquired pneumonia was uncommon, and few tested patients were diagnosed with ...
Strong Buy reiterated with a €8.37 target price following the 21 January 2026 Flash; last close on 22 January 2026: ...
As modern vehicle architecture becomes increasingly complex, the demand for efficient verification and validation grows.
Agilus Diagnostics unveils Illumina NovaSeq X to bolster India’s capacity for NGS at scale: Our Bureau, Bengaluru Wednesday, January 28, 2026, 17:15 Hrs [IST] Agilus Diagnostics ...
Large-scale infrastructure projects, interconnection schemes, and renewable energy developments continue to shape the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results